nodes	percent_of_prediction	percent_of_DWPC	metapath
Verteporfin—Injection site haemorrhage—Epirubicin—liver cancer	0.0272	0.0272	CcSEcCtD
Verteporfin—Injection site haemorrhage—Doxorubicin—liver cancer	0.0252	0.0252	CcSEcCtD
Verteporfin—Injection site inflammation—Epirubicin—liver cancer	0.022	0.022	CcSEcCtD
Verteporfin—Injection site inflammation—Doxorubicin—liver cancer	0.0203	0.0203	CcSEcCtD
Verteporfin—Prostatic disorder—Epirubicin—liver cancer	0.0172	0.0172	CcSEcCtD
Verteporfin—Eczema—Sorafenib—liver cancer	0.016	0.016	CcSEcCtD
Verteporfin—Prostatic disorder—Doxorubicin—liver cancer	0.0159	0.0159	CcSEcCtD
Verteporfin—Peripheral vascular disorder—Epirubicin—liver cancer	0.0149	0.0149	CcSEcCtD
Verteporfin—Peripheral vascular disorder—Doxorubicin—liver cancer	0.0138	0.0138	CcSEcCtD
Verteporfin—Myasthenia—Epirubicin—liver cancer	0.0117	0.0117	CcSEcCtD
Verteporfin—Pneumonia—Sorafenib—liver cancer	0.0112	0.0112	CcSEcCtD
Verteporfin—Acute coronary syndrome—Sorafenib—liver cancer	0.0109	0.0109	CcSEcCtD
Verteporfin—Myocardial infarction—Sorafenib—liver cancer	0.0109	0.0109	CcSEcCtD
Verteporfin—Myasthenia—Doxorubicin—liver cancer	0.0108	0.0108	CcSEcCtD
Verteporfin—Blister—Epirubicin—liver cancer	0.0102	0.0102	CcSEcCtD
Verteporfin—Haemoglobin—Sorafenib—liver cancer	0.01	0.01	CcSEcCtD
Verteporfin—Haemorrhage—Sorafenib—liver cancer	0.00996	0.00996	CcSEcCtD
Verteporfin—Albuminuria—Epirubicin—liver cancer	0.00981	0.00981	CcSEcCtD
Verteporfin—Scotoma—Epirubicin—liver cancer	0.00965	0.00965	CcSEcCtD
Verteporfin—Blister—Doxorubicin—liver cancer	0.00941	0.00941	CcSEcCtD
Verteporfin—Hyperaesthesia—Epirubicin—liver cancer	0.00933	0.00933	CcSEcCtD
Verteporfin—Flushing—Sorafenib—liver cancer	0.00924	0.00924	CcSEcCtD
Verteporfin—Cardiac disorder—Sorafenib—liver cancer	0.00924	0.00924	CcSEcCtD
Verteporfin—Albuminuria—Doxorubicin—liver cancer	0.00908	0.00908	CcSEcCtD
Verteporfin—Angiopathy—Sorafenib—liver cancer	0.00903	0.00903	CcSEcCtD
Verteporfin—Immune system disorder—Sorafenib—liver cancer	0.00899	0.00899	CcSEcCtD
Verteporfin—Injection site pain—Epirubicin—liver cancer	0.00897	0.00897	CcSEcCtD
Verteporfin—Scotoma—Doxorubicin—liver cancer	0.00893	0.00893	CcSEcCtD
Verteporfin—Malnutrition—Sorafenib—liver cancer	0.00867	0.00867	CcSEcCtD
Verteporfin—Hyperaesthesia—Doxorubicin—liver cancer	0.00864	0.00864	CcSEcCtD
Verteporfin—Extravasation—Epirubicin—liver cancer	0.0084	0.0084	CcSEcCtD
Verteporfin—Injection site pain—Doxorubicin—liver cancer	0.0083	0.0083	CcSEcCtD
Verteporfin—Arthropathy—Epirubicin—liver cancer	0.00806	0.00806	CcSEcCtD
Verteporfin—Anaemia—Sorafenib—liver cancer	0.00801	0.00801	CcSEcCtD
Verteporfin—Syncope—Sorafenib—liver cancer	0.00777	0.00777	CcSEcCtD
Verteporfin—Extravasation—Doxorubicin—liver cancer	0.00777	0.00777	CcSEcCtD
Verteporfin—Creatinine increased—Epirubicin—liver cancer	0.0077	0.0077	CcSEcCtD
Verteporfin—Loss of consciousness—Sorafenib—liver cancer	0.00762	0.00762	CcSEcCtD
Verteporfin—Cough—Sorafenib—liver cancer	0.00756	0.00756	CcSEcCtD
Verteporfin—Inflammation—Epirubicin—liver cancer	0.00755	0.00755	CcSEcCtD
Verteporfin—Hypertension—Sorafenib—liver cancer	0.00748	0.00748	CcSEcCtD
Verteporfin—Arthropathy—Doxorubicin—liver cancer	0.00746	0.00746	CcSEcCtD
Verteporfin—Musculoskeletal pain—Epirubicin—liver cancer	0.00742	0.00742	CcSEcCtD
Verteporfin—Arthralgia—Sorafenib—liver cancer	0.00738	0.00738	CcSEcCtD
Verteporfin—Unspecified disorder of skin and subcutaneous tissue—Sorafenib—liver cancer	0.00733	0.00733	CcSEcCtD
Verteporfin—Injection site reaction—Epirubicin—liver cancer	0.00728	0.00728	CcSEcCtD
Verteporfin—Creatinine increased—Doxorubicin—liver cancer	0.00712	0.00712	CcSEcCtD
Verteporfin—Inflammation—Doxorubicin—liver cancer	0.00699	0.00699	CcSEcCtD
Verteporfin—Shock—Sorafenib—liver cancer	0.00696	0.00696	CcSEcCtD
Verteporfin—Nervous system disorder—Sorafenib—liver cancer	0.00694	0.00694	CcSEcCtD
Verteporfin—Skin disorder—Sorafenib—liver cancer	0.00687	0.00687	CcSEcCtD
Verteporfin—Musculoskeletal pain—Doxorubicin—liver cancer	0.00686	0.00686	CcSEcCtD
Verteporfin—Dry eye—Epirubicin—liver cancer	0.00677	0.00677	CcSEcCtD
Verteporfin—Injection site reaction—Doxorubicin—liver cancer	0.00674	0.00674	CcSEcCtD
Verteporfin—Musculoskeletal discomfort—Sorafenib—liver cancer	0.00644	0.00644	CcSEcCtD
Verteporfin—Dyspnoea—Sorafenib—liver cancer	0.00631	0.00631	CcSEcCtD
Verteporfin—Dry eye—Doxorubicin—liver cancer	0.00626	0.00626	CcSEcCtD
Verteporfin—Gastrointestinal disorder—Sorafenib—liver cancer	0.00611	0.00611	CcSEcCtD
Verteporfin—Photosensitivity—Epirubicin—liver cancer	0.00606	0.00606	CcSEcCtD
Verteporfin—Pain—Sorafenib—liver cancer	0.00605	0.00605	CcSEcCtD
Verteporfin—Constipation—Sorafenib—liver cancer	0.00605	0.00605	CcSEcCtD
Verteporfin—Eczema—Epirubicin—liver cancer	0.00592	0.00592	CcSEcCtD
Verteporfin—Urticaria—Sorafenib—liver cancer	0.00562	0.00562	CcSEcCtD
Verteporfin—Photosensitivity—Doxorubicin—liver cancer	0.0056	0.0056	CcSEcCtD
Verteporfin—Body temperature increased—Sorafenib—liver cancer	0.00559	0.00559	CcSEcCtD
Verteporfin—Dermatitis bullous—Epirubicin—liver cancer	0.00556	0.00556	CcSEcCtD
Verteporfin—Eczema—Doxorubicin—liver cancer	0.00548	0.00548	CcSEcCtD
Verteporfin—Osteoarthritis—Epirubicin—liver cancer	0.00532	0.00532	CcSEcCtD
Verteporfin—Diplopia—Epirubicin—liver cancer	0.00532	0.00532	CcSEcCtD
Verteporfin—Hypersensitivity—Sorafenib—liver cancer	0.00521	0.00521	CcSEcCtD
Verteporfin—Dermatitis bullous—Doxorubicin—liver cancer	0.00515	0.00515	CcSEcCtD
Verteporfin—Asthenia—Sorafenib—liver cancer	0.00507	0.00507	CcSEcCtD
Verteporfin—Pruritus—Sorafenib—liver cancer	0.005	0.005	CcSEcCtD
Verteporfin—Blood creatinine increased—Epirubicin—liver cancer	0.00498	0.00498	CcSEcCtD
Verteporfin—Diplopia—Doxorubicin—liver cancer	0.00492	0.00492	CcSEcCtD
Verteporfin—Osteoarthritis—Doxorubicin—liver cancer	0.00492	0.00492	CcSEcCtD
Verteporfin—Liver function test abnormal—Epirubicin—liver cancer	0.00491	0.00491	CcSEcCtD
Verteporfin—Muscular weakness—Epirubicin—liver cancer	0.00469	0.00469	CcSEcCtD
Verteporfin—Dizziness—Sorafenib—liver cancer	0.00468	0.00468	CcSEcCtD
Verteporfin—Blood creatinine increased—Doxorubicin—liver cancer	0.00461	0.00461	CcSEcCtD
Verteporfin—Influenza—Epirubicin—liver cancer	0.0046	0.0046	CcSEcCtD
Verteporfin—Liver function test abnormal—Doxorubicin—liver cancer	0.00454	0.00454	CcSEcCtD
Verteporfin—Rash—Sorafenib—liver cancer	0.00446	0.00446	CcSEcCtD
Verteporfin—Dermatitis—Sorafenib—liver cancer	0.00446	0.00446	CcSEcCtD
Verteporfin—Headache—Sorafenib—liver cancer	0.00443	0.00443	CcSEcCtD
Verteporfin—Muscular weakness—Doxorubicin—liver cancer	0.00434	0.00434	CcSEcCtD
Verteporfin—Influenza—Doxorubicin—liver cancer	0.00425	0.00425	CcSEcCtD
Verteporfin—Nausea—Sorafenib—liver cancer	0.0042	0.0042	CcSEcCtD
Verteporfin—Photosensitivity reaction—Epirubicin—liver cancer	0.0042	0.0042	CcSEcCtD
Verteporfin—Pneumonia—Epirubicin—liver cancer	0.00412	0.00412	CcSEcCtD
Verteporfin—Conjunctivitis—Epirubicin—liver cancer	0.00398	0.00398	CcSEcCtD
Verteporfin—Sweating—Epirubicin—liver cancer	0.00393	0.00393	CcSEcCtD
Verteporfin—Photosensitivity reaction—Doxorubicin—liver cancer	0.00388	0.00388	CcSEcCtD
Verteporfin—Pneumonia—Doxorubicin—liver cancer	0.00381	0.00381	CcSEcCtD
Verteporfin—Haemoglobin—Epirubicin—liver cancer	0.0037	0.0037	CcSEcCtD
Verteporfin—Conjunctivitis—Doxorubicin—liver cancer	0.00369	0.00369	CcSEcCtD
Verteporfin—Haemorrhage—Epirubicin—liver cancer	0.00368	0.00368	CcSEcCtD
Verteporfin—Hypoaesthesia—Epirubicin—liver cancer	0.00366	0.00366	CcSEcCtD
Verteporfin—Pharyngitis—Epirubicin—liver cancer	0.00365	0.00365	CcSEcCtD
Verteporfin—Sweating—Doxorubicin—liver cancer	0.00364	0.00364	CcSEcCtD
Verteporfin—Visual impairment—Epirubicin—liver cancer	0.00355	0.00355	CcSEcCtD
Verteporfin—Eye disorder—Epirubicin—liver cancer	0.00344	0.00344	CcSEcCtD
Verteporfin—Haemoglobin—Doxorubicin—liver cancer	0.00342	0.00342	CcSEcCtD
Verteporfin—Flushing—Epirubicin—liver cancer	0.00341	0.00341	CcSEcCtD
Verteporfin—Cardiac disorder—Epirubicin—liver cancer	0.00341	0.00341	CcSEcCtD
Verteporfin—Haemorrhage—Doxorubicin—liver cancer	0.0034	0.0034	CcSEcCtD
Verteporfin—Hypoaesthesia—Doxorubicin—liver cancer	0.00339	0.00339	CcSEcCtD
Verteporfin—Pharyngitis—Doxorubicin—liver cancer	0.00338	0.00338	CcSEcCtD
Verteporfin—Angiopathy—Epirubicin—liver cancer	0.00334	0.00334	CcSEcCtD
Verteporfin—Immune system disorder—Epirubicin—liver cancer	0.00332	0.00332	CcSEcCtD
Verteporfin—Visual impairment—Doxorubicin—liver cancer	0.00328	0.00328	CcSEcCtD
Verteporfin—Malnutrition—Epirubicin—liver cancer	0.0032	0.0032	CcSEcCtD
Verteporfin—Eye disorder—Doxorubicin—liver cancer	0.00318	0.00318	CcSEcCtD
Verteporfin—Flushing—Doxorubicin—liver cancer	0.00316	0.00316	CcSEcCtD
Verteporfin—Cardiac disorder—Doxorubicin—liver cancer	0.00316	0.00316	CcSEcCtD
Verteporfin—Back pain—Epirubicin—liver cancer	0.0031	0.0031	CcSEcCtD
Verteporfin—Angiopathy—Doxorubicin—liver cancer	0.00309	0.00309	CcSEcCtD
Verteporfin—Immune system disorder—Doxorubicin—liver cancer	0.00308	0.00308	CcSEcCtD
Verteporfin—Vision blurred—Epirubicin—liver cancer	0.00302	0.00302	CcSEcCtD
Verteporfin—Ill-defined disorder—Epirubicin—liver cancer	0.00297	0.00297	CcSEcCtD
Verteporfin—Malnutrition—Doxorubicin—liver cancer	0.00296	0.00296	CcSEcCtD
Verteporfin—Anaemia—Epirubicin—liver cancer	0.00296	0.00296	CcSEcCtD
Verteporfin—Malaise—Epirubicin—liver cancer	0.00289	0.00289	CcSEcCtD
Verteporfin—Vertigo—Epirubicin—liver cancer	0.00288	0.00288	CcSEcCtD
Verteporfin—Syncope—Epirubicin—liver cancer	0.00287	0.00287	CcSEcCtD
Verteporfin—Back pain—Doxorubicin—liver cancer	0.00287	0.00287	CcSEcCtD
Verteporfin—Loss of consciousness—Epirubicin—liver cancer	0.00282	0.00282	CcSEcCtD
Verteporfin—Cough—Epirubicin—liver cancer	0.00279	0.00279	CcSEcCtD
Verteporfin—Vision blurred—Doxorubicin—liver cancer	0.00279	0.00279	CcSEcCtD
Verteporfin—Hypertension—Epirubicin—liver cancer	0.00277	0.00277	CcSEcCtD
Verteporfin—Ill-defined disorder—Doxorubicin—liver cancer	0.00275	0.00275	CcSEcCtD
Verteporfin—Anaemia—Doxorubicin—liver cancer	0.00274	0.00274	CcSEcCtD
Verteporfin—Chest pain—Epirubicin—liver cancer	0.00273	0.00273	CcSEcCtD
Verteporfin—Arthralgia—Epirubicin—liver cancer	0.00273	0.00273	CcSEcCtD
Verteporfin—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—liver cancer	0.00271	0.00271	CcSEcCtD
Verteporfin—Discomfort—Epirubicin—liver cancer	0.00269	0.00269	CcSEcCtD
Verteporfin—Malaise—Doxorubicin—liver cancer	0.00267	0.00267	CcSEcCtD
Verteporfin—Vertigo—Doxorubicin—liver cancer	0.00266	0.00266	CcSEcCtD
Verteporfin—Syncope—Doxorubicin—liver cancer	0.00266	0.00266	CcSEcCtD
Verteporfin—Oedema—Epirubicin—liver cancer	0.00261	0.00261	CcSEcCtD
Verteporfin—Loss of consciousness—Doxorubicin—liver cancer	0.0026	0.0026	CcSEcCtD
Verteporfin—Cough—Doxorubicin—liver cancer	0.00259	0.00259	CcSEcCtD
Verteporfin—Shock—Epirubicin—liver cancer	0.00257	0.00257	CcSEcCtD
Verteporfin—Nervous system disorder—Epirubicin—liver cancer	0.00256	0.00256	CcSEcCtD
Verteporfin—Hypertension—Doxorubicin—liver cancer	0.00256	0.00256	CcSEcCtD
Verteporfin—Skin disorder—Epirubicin—liver cancer	0.00254	0.00254	CcSEcCtD
Verteporfin—Hyperhidrosis—Epirubicin—liver cancer	0.00253	0.00253	CcSEcCtD
Verteporfin—Arthralgia—Doxorubicin—liver cancer	0.00252	0.00252	CcSEcCtD
Verteporfin—Chest pain—Doxorubicin—liver cancer	0.00252	0.00252	CcSEcCtD
Verteporfin—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—liver cancer	0.00251	0.00251	CcSEcCtD
Verteporfin—Discomfort—Doxorubicin—liver cancer	0.00249	0.00249	CcSEcCtD
Verteporfin—Oedema—Doxorubicin—liver cancer	0.00242	0.00242	CcSEcCtD
Verteporfin—Musculoskeletal discomfort—Epirubicin—liver cancer	0.00238	0.00238	CcSEcCtD
Verteporfin—Shock—Doxorubicin—liver cancer	0.00238	0.00238	CcSEcCtD
Verteporfin—Nervous system disorder—Doxorubicin—liver cancer	0.00237	0.00237	CcSEcCtD
Verteporfin—Skin disorder—Doxorubicin—liver cancer	0.00235	0.00235	CcSEcCtD
Verteporfin—Hyperhidrosis—Doxorubicin—liver cancer	0.00234	0.00234	CcSEcCtD
Verteporfin—Dyspnoea—Epirubicin—liver cancer	0.00233	0.00233	CcSEcCtD
Verteporfin—Gastrointestinal disorder—Epirubicin—liver cancer	0.00226	0.00226	CcSEcCtD
Verteporfin—Pain—Epirubicin—liver cancer	0.00224	0.00224	CcSEcCtD
Verteporfin—Constipation—Epirubicin—liver cancer	0.00224	0.00224	CcSEcCtD
Verteporfin—Musculoskeletal discomfort—Doxorubicin—liver cancer	0.0022	0.0022	CcSEcCtD
Verteporfin—Dyspnoea—Doxorubicin—liver cancer	0.00216	0.00216	CcSEcCtD
Verteporfin—Feeling abnormal—Epirubicin—liver cancer	0.00215	0.00215	CcSEcCtD
Verteporfin—Gastrointestinal disorder—Doxorubicin—liver cancer	0.00209	0.00209	CcSEcCtD
Verteporfin—Urticaria—Epirubicin—liver cancer	0.00208	0.00208	CcSEcCtD
Verteporfin—Constipation—Doxorubicin—liver cancer	0.00207	0.00207	CcSEcCtD
Verteporfin—Pain—Doxorubicin—liver cancer	0.00207	0.00207	CcSEcCtD
Verteporfin—Body temperature increased—Epirubicin—liver cancer	0.00207	0.00207	CcSEcCtD
Verteporfin—Feeling abnormal—Doxorubicin—liver cancer	0.00199	0.00199	CcSEcCtD
Verteporfin—Hypersensitivity—Epirubicin—liver cancer	0.00193	0.00193	CcSEcCtD
Verteporfin—Urticaria—Doxorubicin—liver cancer	0.00192	0.00192	CcSEcCtD
Verteporfin—Body temperature increased—Doxorubicin—liver cancer	0.00191	0.00191	CcSEcCtD
Verteporfin—Asthenia—Epirubicin—liver cancer	0.00188	0.00188	CcSEcCtD
Verteporfin—Pruritus—Epirubicin—liver cancer	0.00185	0.00185	CcSEcCtD
Verteporfin—Hypersensitivity—Doxorubicin—liver cancer	0.00178	0.00178	CcSEcCtD
Verteporfin—Asthenia—Doxorubicin—liver cancer	0.00174	0.00174	CcSEcCtD
Verteporfin—Dizziness—Epirubicin—liver cancer	0.00173	0.00173	CcSEcCtD
Verteporfin—Pruritus—Doxorubicin—liver cancer	0.00171	0.00171	CcSEcCtD
Verteporfin—Rash—Epirubicin—liver cancer	0.00165	0.00165	CcSEcCtD
Verteporfin—Dermatitis—Epirubicin—liver cancer	0.00165	0.00165	CcSEcCtD
Verteporfin—Headache—Epirubicin—liver cancer	0.00164	0.00164	CcSEcCtD
Verteporfin—Dizziness—Doxorubicin—liver cancer	0.0016	0.0016	CcSEcCtD
Verteporfin—Nausea—Epirubicin—liver cancer	0.00155	0.00155	CcSEcCtD
Verteporfin—Rash—Doxorubicin—liver cancer	0.00153	0.00153	CcSEcCtD
Verteporfin—Dermatitis—Doxorubicin—liver cancer	0.00152	0.00152	CcSEcCtD
Verteporfin—Headache—Doxorubicin—liver cancer	0.00152	0.00152	CcSEcCtD
Verteporfin—Nausea—Doxorubicin—liver cancer	0.00144	0.00144	CcSEcCtD
